Skip to main content
Premium Trial:

Request an Annual Quote

Advanced Biological Laboratories Gets CE-IVD Mark for HIV Genotyping Assays

NEW YORK — Advanced Biological Laboratories said on Tuesday that it has received CE-IVD marking for its DeepChek sequencing-based assays for HIV genotyping and drug resistance testing.

According to Luxembourg-based ABL, the DeepChek-HIV assays cover the protease/reverse transcriptase and the integrase regions of the virus, respectively, and are intended for use with input RNA extracted from plasma, serum, or whole blood samples.

They are designed for settings running either Sanger sequencing or next-generation sequencing workflows and have been validated with ABL's DeepChek library preparation assays on several of Illumina's NGS platforms including the iSeq 100 instrument, the company added.